Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?

S. Schneeberger, L. Landin, C. Kaufmann, V. S. Gorantla, G. Brandacher, P. Cavadas, W. P.A. Lee, W. C. Breidenbach, R. Margreiter

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.

Original languageEnglish (US)
Pages (from-to)499-502
Number of pages4
JournalTransplantation Proceedings
Volume41
Issue number2
DOIs
StatePublished - Mar 1 2009
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Fingerprint Dive into the research topics of 'Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?'. Together they form a unique fingerprint.

  • Cite this

    Schneeberger, S., Landin, L., Kaufmann, C., Gorantla, V. S., Brandacher, G., Cavadas, P., Lee, W. P. A., Breidenbach, W. C., & Margreiter, R. (2009). Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation? Transplantation Proceedings, 41(2), 499-502. https://doi.org/10.1016/j.transproceed.2009.01.018